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Effect of Early Vasopressin vs Norepinephrine on Kidney
Failure in PatientsWith Septic Shock
The VANISH Randomized Clinical Trial
Anthony C. Gordon, MD; Alexina J. Mason, PhD; Neeraja Thirunavukkarasu, MSc; Gavin D. Perkins, MD; Maurizio Cecconi, MD;
Magda Cepkova, MD; David G. Pogson, MB BCh; Hollmann D. Aya, MD; Aisha Anjum, BSc; Gregory J. Frazier, MSc;
Shalini Santhakumaran, MSc; Deborah Ashby, PhD; Stephen J. Brett, MD; for the VANISH Investigators
IMPORTANCE Norepinephrine is currently recommended as the first-line vasopressor in septic
shock; however, early vasopressin use has been proposed as an alternative.
OBJECTIVE To compare the effect of early vasopressin vs norepinephrine on kidney failure in
patients with septic shock.
DESIGN, SETTING, AND PARTICIPANTS A factorial (2×2), double-blind, randomized clinical trial
conducted in 18 general adult intensive care units in the United Kingdom between February
2013 andMay 2015, enrolling adult patients who had septic shock requiring vasopressors
despite fluid resuscitation within a maximum of 6 hours after the onset of shock.
INTERVENTIONS Patients were randomly allocated to vasopressin (titrated up to 0.06 U/min)
and hydrocortisone (n = 101), vasopressin and placebo (n = 104), norepinephrine and
hydrocortisone (n = 101), or norepinephrine and placebo (n = 103).
MAIN OUTCOMES ANDMEASURES The primary outcomewas kidney failure–free days during
the 28-day period after randomization, measured as (1) the proportion of patients who never
developed kidney failure and (2) median number of days alive and free of kidney failure for
patients who did not survive, who experienced kidney failure, or both. Rates of renal
replacement therapy, mortality, and serious adverse events were secondary outcomes.
RESULTS A total of 409 patients (median age, 66 years; men, 58.2%) were included in the
study, with a median time to study drug administration of 3.5 hours after diagnosis of shock.
The number of survivors who never developed kidney failure was 94 of 165 patients (57.0%)
in the vasopressin group and 93 of 157 patients (59.2%) in the norepinephrine group
(difference, −2.3% [95% CI, −13.0% to 8.5%]). Themedian number of kidney failure–free
days for patients who did not survive, who experienced kidney failure, or both was 9 days
(interquartile range [IQR], 1 to –24) in the vasopressin group and 13 days (IQR, 1 to –25) in the
norepinephrine group (difference, −4 days [95% CI, −11 to 5]). There was less use of renal
replacement therapy in the vasopressin group than in the norepinephrine group (25.4% for
vasopressin vs 35.3% for norepinephrine; difference, −9.9% [95% CI, −19.3% to −0.6%]).
There was no significant difference in mortality rates between groups. In total, 22 of 205
patients (10.7%) had a serious adverse event in the vasopressin group vs 17 of 204 patients
(8.3%) in the norepinephrine group (difference, 2.5% [95% CI, −3.3% to 8.2%]).
CONCLUSIONS AND RELEVANCE Among adults with septic shock, the early use of vasopressin
compared with norepinephrine did not improve the number of kidney failure–free days.
Although these findings do not support the use of vasopressin to replace norepinephrine as
initial treatment in this situation, the confidence interval included a potential clinically
important benefit for vasopressin, and larger trials may be warranted to assess this further.
TRIAL REGISTRATION clinicaltrials.gov Identifier: ISRCTN 20769191
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I n2015, itwasestimated that thereweremore than230000cases of septic shockwithmore than40000deaths in theUnited States each year.1 In addition to treating theunder-
lying infection, the mainstay of cardiovascular resuscitation
in septic shock is intravenous fluids and vasopressor treat-
ment. Norepinephrine is the recommended first-line
vasopressor2but, sincea relativevasopressindeficiency insep-
tic shockwasdescribed, therehasbeengrowing interest in the
useofvasopressinasanadjunctiveagent.3Preclinicalandsmall
clinical studies have suggested that vasopressin may be bet-
ter able tomaintainglomerular filtration rate and improve cre-
atinine clearance compared with norepinephrine.4-6
The largest trial ofvasopressin todate, theVasopressinand
Septic Shock Trial (VASST),7 found no difference inmortality
overallwhenvasopressin (up to0.03U/min)was added to ex-
isting norepinephrine treatment comparedwith norepineph-
rine alone, but therewas a significantly lowermortality in the
patients treated with vasopressin who had less severe shock
(defined as a dose of norepinephrine <15 μg/min). Additional
analyses from VASST and other investigations have sug-
gested that early vasopressin might prevent deterioration in
organ function,5,8particularlykidney function, and thathigher
dosesofvasopressin (upto0.06U/min)maybemoreeffective.9
In addition, it has been proposed that there may be an inter-
actionbetweenvasopressin and corticosteroidswhenused to
treat septic shockand that the combinationofvasopressinand
corticosteroids may improve survival10 and reduce the dura-
tion of shock.11
The Vasopressin vs Norepinephrine as Initial Therapy in
Septic Shock (VANISH) trialwasdesigned to testwhether early
vasopressin use, titrated up to 0.06 U/min, would improve
kidney outcomes compared with norepinephrine.
Methods
Trial Design and Participants
The VANISH trial was a factorial (2×2), multicenter, double-
blind, randomized clinical trial. It was conducted in 18 gen-
eral adult intensive careunits (ICU) in theUnitedKingdombe-
tween February 2013 and May 2015. The trial protocol and
statistical analysis plan are available in Supplement 1.
TheOxfordAresearchethics committeeapproved the trial.
In view of the emergency nature of the trial, a waiver of initial
consentwasgranted.Patientscouldbeenrolledintothetrialwith-
outprospectiveconsentandthenwrittenconsentwasobtained
from thepatient or a personal or professional legal representa-
tiveassoonaspracticallypossible.Forcases inwhicha legal rep-
resentative gave consent, retrospective written consent was
sought once the patient regained decision-making capacity.
Adult patients (≥16 years) who had sepsis (2 of 4 systemic
inflammatory response criteria due to known or suspected
infection12) andwho required vasopressors despite adequate
intravenous fluid resuscitation, as assessedby clinical exami-
nation, central venous pressure, oxygen saturation, or other
physiological parametersusing repeated fluid challengeswere
eligible for the trial. Exclusion criteria were patients who had
received a previous continuous infusion of vasopressors dur-
ing this ICU admission, an ongoing requirement for systemic
steroid treatment (ie, known adrenal insufficiency or regular
systemic steroid therapywithin the last 3months), end-stage
kidney failure, known mesenteric ischemia, Raynaud phe-
nomenon, systemic sclerosis or other vasospastic disease, a
medical team that was not committed to full active treat-
ment, known pregnancy, enrollment in another interven-
tional trial thatmight interactwith the study drugs, or hyper-
sensitivity to any of the study drugs.
Ethnicitywas classifiedbasedonmedical records, asmost
patients lackedcapacity toprovide this informationat the time
of their study enrollment. Documentation of ethnicity in pa-
tients’ medical records is standard practice within the UK
NationalHealthService.Themaincategoriesof ethnicitywere
white, black, Asian, and other. Because the vast majority of
study participants were white, the descriptive statistics uti-
lized a simplified dichotomization of white vs other.
Randomization andMasking
Enrollment, randomization, and data collection were con-
ducted via an online system (InForm, Oracle). Patients were
assigned to 1 of 4 treatment groups (vasopressin and hydro-
cortisone, vasopressin and placebo, norepinephrine and hy-
drocortisone, or norepinephrine and placebo) on a 1:1:1:1 ba-
sis with variable block size randomization (4 and 8) using
computer-generatedrandomnumbers, stratifiedbycenter.The
allocation sequence was prepared by an independent statis-
tician in the Imperial Clinical Trials Unit and concealed from
all investigators and treating clinicians.
Ampoules of vasopressin (Ferring), norepinephrine
(Aguettant), and hydrocortisone phosphate (Amdipharm
Mercury) weremasked by overlabeling on the body and neck
of normal drug ampoules.Matching placebo ampoules (0.9%
saline)weremanufactured by Sharp Clinical Services (United
Kingdom) who carried out all labeling and treatment pack
preparation.
Clinical Management
Patients were allocated to receive either vasopressin (titrated
up to0.06U/min) ornorepinephrine (titratedup to 12μg/min)
as the initial vasopressor infusion (study drug 1) via a central
venous catheter, and titrated tomaintain the target mean ar-
terial pressure (MAP). The protocol recommended a MAP of
65 to 75mmHg, but this could be altered by the treating phy-
sician if clinically indicated.
Once the maximum infusion rate of study drug 1 was
reached, patients received study drug 2, either 50 mg of hy-
drocortisone phosphate or placebo, administered as an intra-
venousbolusevery6hours for5days, every 12hours for3days,
and then once daily for 3 days, as previously reported.13 The
drug could be weaned more quickly if the shock had already
resolved.
If the patient was still hypotensive after the first dose of
study drug 2 then additional open-label catecholamine vaso-
pressorscouldbeadministered.As thepatient recovered,open-
label catecholaminevasopressorswere reduced first andonly
once thepatientwasweanedoff open-label vasopressorswas
studydrug 1 then reduced.Once studydrug 1wasweanedoff,
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if therewas recurrent hypotensionwithin 24hours, the study
drug was restarted; if hypotension recurred after 24 hours,
open-label vasopressors were used at local physician discre-
tion.All other treatmentwas at physiciandiscretion, basedon
the Surviving Sepsis Campaign guidelines at that time.14
Patients could present and be recruited from any part of
the hospital prior to ICU admission. Although the aimwas to
use study drug 1 as the initial vasopressor, study drugs could
notbe stored inmultiple locationswithin thehospitals. There-
fore, in an emergency when immediate treatment was re-
quired, patients could be initially resuscitated using usual
(open-label) clinically prescribed vasopressors. In this situa-
tion, thepatienthad tobeenrolled into the trialwithin6hours
of commencing the open-label vasopressor infusion. As the
studydrug infusionwas titratedup, as detailed above, the ini-
tial open-label vasopressor infusionwasweanedoff asquickly
as possible to maximize the study drug infusion rate.
OutcomeMeasures
Theprimary outcomeof the trialwas kidney failure–free days
(ie, the number of days alive and free of kidney failure), de-
fined by theAcuteKidney InjuryNetwork (AKIN) group stage
3definition,15 during the28days after randomization,withno
additional penalty for death. This outcome measure was not
normally distributed and had a large spike in frequency at 28
days, the point at which the measure was truncated, repre-
senting survivorswhoneverdevelopedkidney failure. There-
fore, the prospective planwas to report the data using 2 sum-
mary measures: (1) the proportion of survivors who never
developedkidney failure (the spike at 28days) and (2) theme-
dian number of days alive and free of kidney failure for the
other patients who did not survive, who experienced kidney
failure, or both at any time.
Secondary outcomes included rates and duration of renal
replacement therapy; length of kidney failure in survivors and
nonsurvivors; 28-day, ICU,andhospitalmortality rates; andor-
gan failure–free days in the first 28 days, assessed using the
Sequential Organ Failure Assessment (SOFA) score.16
Statistical Analysis
Asample size of 400was chosen to provide 80%power to de-
tect a 20% to 25% relative reduction of risk of developing
kidney failure if treatedwith vasopressin comparedwithnor-
epinephrine, assuming an overall incidence of acute kidney
failure of 30% to 50%8,11 and a significance level of .05. The
calculations were based on simulation, assuming a Mann-
Whitney U test for analysis. To allow for a 3% withdrawal of
consent in line with previous critical care studies within the
United Kingdom,17 412 patients was the recruitment target.
The primary analysis tested for a difference between the
distribution of kidney failure–free days for all patients ran-
domized to vasopressin compared with those randomized to
norepinephrineusingaMann-WhitneyU test. Themainanaly-
sis was a modified intention-to-treat basis (patients who did
not receive study drug because they had died or recovered or
were found to be ineligible after randomization were ex-
cluded).However,becausenotall patientswould require study
drug2,analysiswasalsocarriedoutonanas-treatedbasis,with
patients not requiring study drug 2 allocated to the placebo
group, and reallocation of any crossovers. A further per-
protocol analysiswas carriedout inwhich anypatients not re-
ceiving the allocated study drugs or crossovers were ex-
cluded. Logistic regressionmodels andCox regressionmodels
were used to compare renal replacement therapy andmortal-
ity between the 4 treatment groups and test for a potential
vasopressin and hydrocortisone interaction on an intention-
to-treat basis accounting for study site using a hierarchical
model for the logistic regression and stratification for the Cox
model. All analyses were carried out using R (R Foundation),
version 3.1.3, and a P value less than .05 was considered sta-
tistically significant using 2-sided tests.
Results
Figure 1 shows the flowof patients through the trial. Themost
frequent reason for screening failurewasexceeding the6-hour
recruitment window. A total of 421 patients were random-
ized. Sevenpatientswere found tobe ineligible after random-
ization but before receiving any study drug and 5 patients or
legal representatives withheld or withdrew consent after in-
clusion in the trial; thesepatientswereexcluded fromall analy-
ses. One patient refused ongoing participation in the trial af-
ter inclusion, including28-day follow-up, but allowedexisting
data to be included in the analyses. Therefore, 409 patients
were included at baseline for safety data and some secondary
outcome analyses as indicated and 408 patients were in-
cluded in theprimary intention-to-treat analysis. In total, 8pa-
tients in placebo groups were given open-label hydrocorti-
sone as “rescue” therapy or for other clinical indications and
2 patients in the norepinephrine groups were given open-
label vasopressin (1 of whom was also 1 of the 8 given open-
label hydrocortisone), and these patients were included as
crossovers in the as-treatedanalysis. Thepatientswhodidnot
receive study drug 2 (Figure 1) were allocated to the placebo
group in theas-treatedanalysis.All crossoversandpatientsnot
receiving the second study drugwere excluded from the per-
protocol analysis.
The treatment groups were well balanced at baseline
(Table 1). The studydrugswere startedat amedianof 3.5hours
after the diagnosis of shock. In 15% of patients, study drug 1
was the first vasopressor administered. For the 309 patients
(76%) receiving norepinephrine at randomization, the me-
dian dose of open-label norepinephrine at baseline was
0.16 μg/kg/min. TheMAP in all treatment groups was similar
at baseline and over the first 7 days (Figure 2A; eFigure 1A in
Supplement 2) and vasopressin spared the total dose of nor-
epinephrine required to maintain the blood pressure
(Figure 2B).
There was no significant difference in the distribution of
kidney failure–freedaysbetweenvasopressinandnorepineph-
rine groups, P = .88 (Figure 3). The number of survivors who
never developedkidney failurewas94of 165patients (57.0%)
in the vasopressin group and 93 of 157 patients (59.2%) in the
norepinephrine group (absolute difference, −2.3% [95% CI,
−13.0% to 8.5%]) (Table 2). The median number of kidney
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failure–free days in the other patients who died, experienced
kidney failure, or both at any time was 9 (interquartile range
[IQR], 1 to 24) in the vasopressin group and 13 (IQR, 1 to 25) in
the norepinephrine group (absolute difference, −4 days [95%
CI, −11 to 5]). Similar resultswere obtainedwhenusing the se-
rum creatinine values and urine output values separately to
define kidney failure (eTable 2 in Supplement 2), and the as-
treated andper-protocol analyses gave similar results (eTable
3 in Supplement 2).
Similar quantities of intravenous fluid were given to all
groups, and total fluidbalance, serum lactate levels, andheart
rate were similar in all groups (eTables 4-7 in Supplement 2).
Serum creatinine levels were lower and urine output slightly
higher over the first 7 days in the vasopressin group com-
paredwith thenorepinephrinegroup (Figure4andeTables8A
and 9A in Supplement 2) and the rate of renal replacement
therapy usewas 25.4% in the vasopressin group and 35.3% in
the norepinephrine group (odds ratio, 0.40 [95% CI, 0.20-
0.73]) (Table 2). There was no significant difference in mor-
tality rates between vasopressin and norepinephrine groups
(28-daymortality, 30.9% in the vasopressin groupvs 27.5% in
thenorepinephrine group; absolute difference, 3.4% [95%CI,
−5.4% to 12.3%]), and hydrocortisone and placebo groups
(28-daymortality, 30.8% in thehydrocortisonegroupvs27.5%
in theplacebogroup; absolutedifference, 3.3%[95%CI, −5.5%
to 12.1%]) (Table2; eFigure4A inSupplement2), and therewas
no significant interactionbetweenvasopressin andhydrocor-
tisone (P = .98 from Cox regressionmodel for 28-daymortal-
ity). Therewerenodifferences in rates of otherneworgan fail-
ures or organ failure–free days between vasopressin and
norepinephrine groups (eTable 10 in Supplement 2).
In the vasopressin group 22 patients had a total of 29 se-
rious adverse events and 17 patients in the norepinephrine
group had 19 events. The breakdown of all serious adverse
Figure 1. Recruitment, Randomization, and Patient Flow in the VANISH Trial
2213 Patients assessed for eligibility
1792 Excluded a
90 Did not meet 2 of the 4  systematic
inflammatory response criteria
1236 Received open-label vasopressor
for >6 h
339 Regular steroid therapy within the
last 3 months
4 Adrenal dysfunction
78 End-stage renal failure
6 Pregnancy
71 Mesenteric ischemia
19 Vasospastic diseases
157 Medical team not committed to full
active treatment
31 Enrolled in another trial with potential
drug interaction
26 Consent declined or unable to consent
1 Other
88 Previous vasopressor infusion during
current ICU admission
421 Randomized
80 Received study drug 2
21 Did not receive study drug 2
1 Received open-label
hydrocortisone
89 Received study drug 2
15 Did not receive study drug 2
2 Received open-label
hydrocortisone
68 Received study drug 2
33 Did not receive study drug 2
1 Received open-label
hydrocortisone
1 Received open-label
vasopressin
65 Received study drug 2
38 Did not receive study drug 2
1 Received open-label
hydrocortisone
1 Received open-label
vasopressin + hydrocortisone
4 Received open-label
hydrocortisone
100 Included in intention-to-treat
analysis
104 Included in intention-to-treat
analysis
101 Included in intention-to-treat
analysis
103 Included in intention-to-treat
analysis
1 Refused ongoing participation
106 Randomized to receive
vasopressin (study drug 1) +
 hydrocortisone (study drug 2)
101 Received study drug 1
5 Did not receive study drug 1
1 Declined consent
4 Ineligible and not given
study drug
107 Randomized to receive
vasopressin (study drug 1) +
placebo (study drug 2)
104 Received study drug 1
3 Did not receive study drug 1
1 Declined consent
2 Ineligible and not given
study drug
102 Randomized to receive
norepinephrine (study drug 1) +
hydrocortisone (study drug 2)
101 Received study drug 1
1 Did not receive study drug 1
(declined consent)
106 Randomized to receive
norepinephrine (study drug 1) +
placebo (study drug 2)
103 Received study drug 1
3 Did not receive study drug 1
2 Declined consent
1 Ineligible and not given
study drug
ICU indicates intensive care unit.
a Patients could meet more than 1 exclusion criteria.
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Table 1. Baseline Characteristics for PatientsWith Septic Shock
Vasopressin
+ Hydrocortisone
(n = 101)
Vasopressin
+ Placebo
(n = 104)
Norepinephrine
+ Hydrocortisone
(n = 101)
Norepinephrine
+ Placebo
(n = 103)
Total Trial
Population
(n = 409)
Age, median (IQR), y 66 (57-76) 67 (59-77) 63 (52-76) 66 (54-76) 66 (54-77)
Men, No. (%) 59 (58) 52 (50) 62 (61) 65 (63) 238 (58)
Weight, median (IQR), kg 75 (63-90) 70 (60-85) 75 (65-89) 73 (64-90) 75 (62-87)
BMI, median (IQR) 26 (23-32) 24 (22-29) 26 (23-30) 25 (23-30) 26 (22-30)
Caucasian ethnicity, No. (%) 85 (84) 89 (86) 87 (86) 88 (85) 349 (85)
Recent surgical history, No. (%)a 17 (17) 21 (20) 18 (18) 17 (17) 73 (18)
APACHE II score, median (IQR) 24 (19-30) 24 (19-29) 24 (20-30) 23 (18-30) 24 (19-30)
Preexisting conditions, No. (%)
Ischemic heart disease 20 (20) 11 (11) 12 (12) 19 (18) 62 (15)
Severe COPD 2 (2) 4 (4) 6 (6) 3 (3) 15 (4)
Chronic kidney failure 9 (9) 8 (8) 5 (5) 5 (5) 27 (7)
Cirrhosis 5 (5) 3 (3) 2 (2) 5 (5) 15 (4)
Cancer 14 (14) 11 (11) 8 (8) 14 (14) 47 (11)
Immunocompromised 9 (9) 4 (4) 8 (8) 7 (7) 28 (7)
Diabetes 19 (19) 20 (19) 22 (22) 29 (28) 90 (22)
Organ failure, No. (%)b
Respiratory 32 (32) 39 (38) 40 (40) 38 (38) 149 (37)
Kidney 19 (19) 19 (18) 24 (24) 23 (22) 85 (21)
Liver 4 (4) 4 (4) 6 (6) 6 (7) 20 (5)
Hematological 6 (6) 6 (6) 6 (6) 4 (4) 22 (6)
Neurological 33 (35) 33 (33) 32 (34) 30 (31) 128 (33)
Physiological variables,
median (IQR)
Mean arterial pressure,
mm Hg
71 (62-80) 69 (62-75) 68 (61-75) 70 (63-78) 70 (62-77)
Heart rate, beats/min 98 (85-109) 96 (84-108) 99 (83-112) 96 (84-110) 97 (84-110)
Central venous pressure,
mm Hgc
12 (9-17) 13 (10-16) 13 (9-17) 13 (8-17) 13 (9-17)
Lactate, mmol/L 2.1 (1.4-4.3) 2.3 (1.5-3.9) 2.6 (1.4-4.5) 2.2 (1.4-3.2) 2.3 (1.4-4)
PaO2/FIO2, mm Hg 190
(122-318)
189
(122-301)
171
(104-264)
195
(130-328)
188
(121-302)
Creatinine, mg/dL 1.36
(0.89-2.69)
1.26
(0.83-2.02)
1.44
(0.83-2.26)
1.5
(0.84-2.32)
1.38
(0.84-2.32)
Bilirubin, mg/dL 0.94
(0.47-1.62)
0.99
(0.53-1.67)
0.85
(0.51-1.42)
0.79
(0.45-1.45)
0.88
(0.47-1.58)
Platelets, ×103/μL 194
(122-289)
176
(116-284)
182
(125-293)
198
(122-270)
188
(121-288)
GCS 14 (6-15) 14 (4-15) 14 (3-15) 14 (5-15) 14 (4-15)
Mechanical ventilation,
No. (%)
55 (54) 58 (56) 62 (61) 61 (59) 236 (58)
Renal replacement therapy,
No. (%)
2 (2) 4 (4) 2 (2) 3 (3) 11 (3)
Volume of IV fluid
in previous 4 h,
median (IQR), mL
1200
(757-2021)
1092
(725-2010)
1168
(606-2000)
1100
(613-2132)
1134
(662-2039)
Patients receiving
open-label vasopressor
at randomization, No. (%)
91 (90) 89 (86) 86 (85) 82 (80) 348 (85)
Time from onset of shock
to receiving first study drug,
median (IQR), h
3.2
(1.8-5)
3.5
(2-5.4)
3.7
(1.7-5)
3.5
(1.4-5.4)
3.5
(1.8-5.2)
Norepinephrine dose
at randomization,
median (IQR), μg/kg/min
0.16
(0.1-0.3)
(n = 76)
0.15
(0.1-0.28)
(n = 79)
0.2
(0.12-0.42)
(n = 81)
0.16
(0.1-0.27)
(n = 73)
0.16
(0.1-0.31)
(n = 309)
Source of infection, No. (%)
Lung 43 (44) 39 (38) 44 (45) 39 (38) 165 (41)
Abdomen 20 (20) 26 (25) 25 (26) 22 (22) 93 (23)
Soft tissue or line 5 (5) 5 (5) 3 (3) 6 (6) 19 (5)
Other 30 (31) 32 (31) 26 (27) 35 (34) 123 (31)
Abbreviations: APACHE, Acute
Physiology and Chronic Health
Evaluation (range 0-72, a higher score
corresponds tomore severe illness
and a higher risk of death); BMI, body
mass index (calculated as weight in
kilograms divided by height in meters
squared); COPD, chronic obstructive
pulmonary disease; GCS, Glasgow
Coma Score (range 3-15, a lower score
corresponds to a greater depression
of consciousness); IQR, interquartile
range; IV, intravenous; PaO2/FIO2,
arterial oxygen partial pressure to
fractional inspired oxygen.
SI conversion factor: To convert
creatinine to μmol/L, multiply by
88.4; bilirubin to μmol/L, multiply
by 17.104.
a Recent surgery is defined as
admitted to intensive care unit
following surgery
bKidney failure is defined as having
acute kidney injury stage 3; other
organ failures defined as having a
Sequential Organ Failure
Assessment score of 3 or more.
c Central venous pressure was only
recorded in 234 patients at baseline.
See eTable 1 in Supplement 2 for
numbers of other missing values
at baseline.
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events by treatment group is given in Table 2. In serious ad-
verse events judged by the treating physician as at least
“possibly related” to the study drugs, the mean dose of
vasopressin on the day of the event or the day before was
Figure 3. Kidney Failure–Free Days by Randomized Treatment Group
Kidney failure–free days per treatment group (primary outcome) 
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The column at 28 days represents survivors who never developed kidney failure, other columns represent patients who did not survive, who experienced kidney
failure, or both at any time.
Figure 2. Mean Arterial Pressure andMaximumTotal (Study andOpen-Label) Norepinephrine Dose Over the First 7 Days by Study Drug 1
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Table 2. OutcomeData in the 4 Treatment Groups and Comparison of the Vasopressin GroupWith the Norepinephrine Group
Vasopressin Norepinephrine
Vasopressin
vs Norepinephrine,
Absolute Difference
(95% CI)bHydrocortisonea Placebo Totala Hydrocortisone Placebo Total
28-d Survivors who never
developed kidney failure,
No./total (%)c
46/81 (56.8) 48/84 (57.1) 94/165 (57.0) 46/77 (59.7) 47/80 (58.8) 93/157 (59.2) −2.3 (−13.0 to 8.5)d
Kidney failure–free days
in other patients,
median (IQR), de
5 (0-23) 12 (1-25) 9 (1-24) 13 (0-25) 14 (1-24) 13 (1-25) −4 (−11 to 5)d
28-d Mortality, No./total (%) 33/100 (33.0) 30/104 (28.8) 63/204 (30.9) 29/101 (28.7) 27/103 (26.2) 56/204 (27.5) 3.4 (−5.4 to 12.3)
ICU mortality, No./total (%) 32/100 (32.0) 26/104 (25.0) 58/204 (28.4) 24/101 (23.8) 27/103 (26.2) 51/204 (25.0) 3.4 (−5.2 to 12.0)
Hospital mortality,
No./total (%)
35/100 (35.0) 33/104 (31.7) 68/204 (33.3) 31/101 (30.7) 29/103 (28.2) 60/204 (29.4) 3.9 (−5.1 to 12.9)
Kidney failure, No./total (%) 41/101 (40.6) 46/104 (44.2) 87/205 (42.4) 46/101 (45.5) 51/103 (49.5) 97/204 (47.5) −5.1 (−15.2 to 5.0)
Survivors 21/67 (31.3) 26/74 (35.1) 47/141 (33.3) 26/72 (36.1) 29/76 (38.2) 55/148 (37.2) −3.8 (−15.5 to 7.9)
Nonsurvivors 20/33 (60.6) 20/30 (66.7) 40/63 (63.5) 20/29 (69) 22/27 (81.5) 42/56 (75) −11.5 (−29.6 to 6.6)
Duration of kidney failure,
median (IQR), d
4 (1 to 7) 2 (1 to 6) 3 (1 to 7) 3 (2 to 6) 4 (2 to 8) 4 (2 to 8) −1 (2 to 0)
Survivors 4 (2 to 7) 3 (2 to 8) 4 (2 to 8) 4 (2 to 8) 4 (3 to 8) 4 (2 to 8) 0 (−3 to 2)
Nonsurvivors 2 (1 to 7) 2 (1 to 3) 2 (1 to 7) 3 (2 to 5) 2 (1 to 8) 3 (2 to 7) −1 (−3 to 0)
Use of RRT, No./total (%) 29/101 (28.7) 23/104 (22.1) 52/205 (25.4) 32/101 (31.7) 40/103 (38.8) 72/204 (35.3) −9.9 (−19.3 to −0.6)
Survivors 15/67 (22.4) 13/74 (17.6) 28/141 (19.9) 15/72 (20.8) 18/76 (23.7) 33/148 (22.3) −2.4 (−12.5 to 7.7)
Nonsurvivors 14/33 (42.4) 10/30 (33.3) 24/63 (38.1) 17/29 (58.6) 22/27 (81.5) 39/56 (69.6) −31.5 (−50.2 to −12.9)
Duration of RRT,
median (IQR), d
4 (2 to 7) 3 (2 to 5) 3 (2 to 7) 3 (2 to 8) 4 (2 to 8) 3 (2 to 8) 0 (−2 to 2)
Survivors 4 (2 to 8) 3 (3 to 14) 4 (2 to 10) 4 (2 to 10) 6 (2 to 12) 5 (2 to 11) −1 (−4 to 2)
Nonsurvivors 4 (1 to 7) 2 (1 to 4) 2 (1 to 6) 3 (2 to 4) 3 (2 to 6) 3 (2 to 6) −1 (−2 to 2)
No. weaned from
vasopressors for >24 h,
No./total (%)
88/101 (87.1) 91/104 (87.5) 179/205 (87.3) 91/101 (90.1) 88/103 (85.4) 179/204 (87.7) 0.4 (−6.8 to 6.0)
Time to shock reversal,
median (IQR), h
50 (28 to 92) 59 (27 to 112) 51 (28 to 99) 46 (23 to 72) 44 (23 to 90) 45 (23 to 75) 6 (−4 to 20)
Use of inotropes,
No./total (%)f
31/101 (30.7) 24/104 (23.1) 55/205 (26.8) 24/101 (23.8) 17/103 (16.5) 41/204 (20.1) 6.7 (−1.5 to 14.9)
Duration of
mechanical ventilation,
median (IQR), d
5 (2 to 10) 6 (3 to 12) 5 (2 to 10) 5 (2 to 16) 5 (2 to 12) 5 (2 to 13) 0 (−2 to 2)
Mean total SOFA score,
mean (SD)
6.1 (3.4) 5.8 (3.1) 6.0 (3.3) 6.1 (3.1) 6.3 (3.5) 6.2 (3.3) −0.2 (−0.9 to 0.4)
ICU length of stay,
median (IQR), d
6 (3 to 10) 7 (3 to 14) 7 (3 to 11) 5 (3 to 15) 6 (3 to 11) 5 (3 to 13) 2 (−1 to 3)
Hospital length of stay,
median (IQR), d
13 (7 to 31) 17 (9 to 40) 16 (7 to 36) 16 (8 to 42) 15 (8 to 36) 16 (8 to 38) 0 (−5 to 4)
Patients who had
≥1 serious adverse events,
No./total (%)
9/101 (8.9) 13/104 (12.5) 22/205 (10.7) 11/101 (10.9) 6/103 (5.8) 17/204 (8.3) 2.5 (−3.3 to 8.2)
Digital ischemiag 4/101 (4.0) 7/104 (6.7) 11/205 (5.4) 2/101 (2.0) 1/103 (1.0) 3/204 (1.5) 3.9 (−0.1 to 7.9)
Mesenteric ischemiag 2/101 (2.0) 3/104 (2.9) 5/205 (2.4) 4/101 (4.0) 1/103 (1.0) 5/204 (2.5) 0.0 (−3.0 to 3.0)
Life-threatening
arrhythmiag
2/101 (2.0) 0/104 (0.0) 2/205 (0.98) 1/101 (1.0) 4/103 (3.9) 5/204 (2.5) −1.5 (−4.5 to 1.5)
Acute coronary syndromeg 4/101 (4.0) 3/104 (2.9) 7/205 (3.4) 2/101 (2.0) 0/103 (0.0) 2/204 (1.0) 2.5 (−0.9 to 5.8)
Otherg 2/101 (2.0) 2/104 (1.9) 4/205 (2.0) 3/101 (3.0) 1/103 (1.0) 4/204 (2.0) 0.0 (−2.7 to 2.7)
Abbreviations: IQR, interquartile range; RRT, renal replacement therapy;
SOFA, Sequential Organ Failure Assessment (range 0-20, a higher score
corresponds tomore severe organ failure).
a One patient in the vasopressin and hydrocortisone group refused ongoing
participation in the trial after inclusion, including 28-d follow-up, but allowed
existing data to be included in the analyses. Their data have been used where
possible, therefore the denominator varies between 104 of 105 patients or
204 of 205 patients.
bAbsolutedifference inpercentage for binary variables anddifference inmedians
for continuous variables. The95%confidence intervals for thedifference
in medians were calculated using bootstrapping; values may not sum
due to rounding.
c 28-day Survivors as a proportion of patients with no kidney failure at baseline
(1 patient with no baseline kidney failure data was excluded).
d Primary outcome.
e Other patients = those who had kidney failure, died, or both at any time.
f Inotropes defined as dobutamine, epinephrine, milrinone, dopamine,
dopexamine.
g The number of serious adverse events represents the number of patients who
had that subcategory of event. Patients may have hadmore than 1 event.
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0.06U/min and themeandoseof norepinephrine or epineph-
rine was 0.55 μg/kg/min (0.33 μg/kg/min in the vasopressin
group and 0.79 μg/kg/min in the norepinephrine group).
Rates of vasopressin and norepinephrine infusion are
shown in eFigures 1B-D and 2 in Supplement 2. There was no
difference in serum creatinine, urine output, rates of kidney
failure, use of renal replacement therapy, mortality, or seri-
ous adverse events between thehydrocortisonegroupand the
placebo group (eTables 8B, 9B, and 11 and eFigures 3A-B and
4B in Supplement 2).
Discussion
In this multicenter, factorial (2×2), double-blind, randomized
clinical trial, early use of vasopressin to treat septic shock did
not increase the number of kidney failure–free days compared
with norepinephrine. Mortality rates were similar between all
groups and there was no interaction on outcome between va-
sopressin and corticosteroids. Although these findings do not
support theuseofvasopressin to replacenorepinephrineas ini-
tial treatment in this situation, the confidence interval in-
cluded apotential clinically important benefit for vasopressin,
and larger trials may be warranted to assess this further.
The rationale for this trial was based on the results of the
previousVASST study.7 Although therewas no significant dif-
ference in mortality rates in the overall septic shock popula-
tion in that trial, therewas a lowermortality rate in the apriori
definedsubgroupofpatientswhohadlesssevereshocktreated
withvasopressincomparedwithnorepinephrine (28-daymor-
tality relative risk, 0.74 [95% CI, 0.55 to 1.01], P = .05). There
was no difference in mortality in those who had more severe
shock (definedasnorepinephrine≥15μg/minatbaseline).Pos-
sible explanations for the VASST result might be (1) that vaso-
pressin was more effective when used earlier before patients
had become too sick (the mean time to study drug initiation
was approximately 12 hours after meeting eligibility), (2) that
the patients with more severe shock might have required a
higher dose of vasopressin because the maximum rate of va-
sopressinwas limited to0.03U/min, (3) that therewasaharm-
ful interaction between vasopressin and high-dose norepi-
nephrine,or(4)itcouldhavebeenachancefindinginasubgroup
analysis, although the subgroups were large and prospec-
tively defined, and randomizationwas stratifiedby subgroup.
Further analyses from VASST suggested that vasopressin
might improvekidney function inpatientsat riskofkidney fail-
ure and reduce rates of progression to kidney failure and loss,
but that it had no effect if acute kidney failurewas already es-
tablished at the time of study inclusion.8 This was supported
byevidence fromastudybyLauzier andcolleagues5 thatdem-
onstrated an improvement in creatinine clearancewhenvaso-
pressin was started in the first 12 hours of developing vasodi-
latory shock. Similarly in VASST, patients enrolled in the first
12hours tendedtohavebetteroutcomeswithvasopressin treat-
ment comparedwith norepinephrine, but not if enrolled after
12 hours.7 For this reason patients in this studywere random-
izedas early aspossible, andat amaximumof6hours afterde-
veloping hypotension. Despite this early recruitment, a num-
ber of patients already had developed acute kidney failure at
the time of inclusion. However, there was no significant dif-
ference in thenumberofpatientswhohadkidney failureat any
time or progressed to kidney failure after randomization. Al-
though there was no significant difference in rates of kidney
failure, there was a lower rate of use of renal replacement
therapy in thepatients treatedwithvasopressin. Theuseof re-
nal replacement therapywas not controlled in this trial, and it
was started based on local clinical decision. It is therefore not
possible to know why renal replacement therapy was or was
not started. Because the trial was double-blinded, it is un-
likely to be due to any obvious clinician bias. It is possible the
Figure 4. Serum Creatinine and Urine Output Over the First 7 Days by Study Drug 1
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difference in rates of renal replacement therapy reflects the
slightly lower creatinine values andhigher urine outputs seen
in the patients treated with vasopressin, particularly on days
3 through 6. Although use of renal replacement therapy was
not theprimaryoutcomeof this trial, it is an importantpatient-
centeredoutcome, and therefore this resultmaybe important
when planning patient treatment strategies.
To ensure that patients with more severe shock were
treatedwith an adequate dose of vasopressin, the dose of va-
sopressinwas titratedup to0.06U/min, double thedoseused
in VASST. In another randomized clinical trial, a dose of
0.067 U/min restored cardiovascular function more effec-
tively than 0.033 U/min, without a difference in adverse
events.9 In the previous pilot trial, an infusion rate of
0.06U/minofvasopressin led tomeanplasma levelsof around
300 pmol/L, well above the physiological levels seen in other
shock states.11 Although the trial by Lauzier et al,5 which had
demonstrated an improved creatinine clearance, used a vaso-
pressin dose up to 0.2 U/min, there was concern that higher
dosesmight lead to adverse effects, such as ischemia fromex-
cessive vasoconstriction. The mean dose of vasopressin was
0.06U/min, and themeandoseofnorepinephrineor epineph-
rine was 0.55 μg/kg/min, when the potentially drug-related
serious adverse events occurred. In view of the uncertainty
about what is the ideal blood pressure to target in septic
shock,18 cliniciansneed tobalance thepotential benefits of an
increased blood pressure against the risk of vasopressor-
related adverse events, particularly at high dose and should
set blood pressure targets for individual patients.
Theotherpotentially important findingfromVASSTthat in-
formed this trial was the potential interactionwith corticoste-
roids. There are several possiblebiological interactions includ-
ing that vasopressin binds to V1b receptors in the anterior
pituitary that then leads to adrenocorticotropin hormone
release19 and corticosteroids have been shown to restore
cytokine-mediateddown-regulationofvasopressinreceptors.20
Patients in VASST who received vasopressin and corticoste-
roidshad reducedmortality rates comparedwithpatientswho
received norepinephrine and corticosteroids. In contrast with
patients who did not receive corticosteroids, patients treated
with norepinephrine had better outcomes.10 Other retrospec-
tive studies also suggested that patients treatedwith the com-
bination of vasopressin and corticosteroids had reducedmor-
tality rates compared with patients receiving vasopressin
alone.21,22 In view of the Surviving Sepsis Guidelines that rec-
ommend only using hydrocortisone (200 mg/d) if hypoten-
sion is not responding to fluid and vasopressor therapy,2 corti-
costeroidswere only administered once studydrug 1was at its
maximal infusion rate (vasopressin0.06U/minornorepineph-
rine 12 μg/min). As in the pilot study,11 corticosteroids reduced
vasopressin requirements but there was no difference inmor-
tality rates and no evidence of an interaction between vaso-
pressin and corticosteroids on outcome. Although not all pa-
tients required study drug 2 (hydrocortisone or placebo), the
resultsweresimilar in theas-treatedandtheper-protocolanaly-
ses. However, because many patients did not require or re-
ceive study drug 2, the power to assess an interactionwas lim-
ited and restricts the interpretation of this finding.
Limitations of this study need to be considered. Themul-
ticenter nature of the trial was designed to test the effective-
ness of early vasopressin use in the treatment of septic shock
in normal clinical practice. Other co-interventions, timing of
initiation of renal replacement therapy, or levels of hemody-
namicmonitoring were not controlled, other than specifying
that sites should follow the international guidelines.14 Be-
cause the trial was blinded and randomization was stratified
by center,wewould expect these other factors to be balanced
betweengroups and thereforeunlikely to affect theoverall re-
sult. Another important limitation is that only short timeout-
comes,28-dayandhospitalmortalitywerecollected,andthere-
fore any long-term differences between treatment groups
cannotbeassessed.Similarly,noformalhealtheconomicanaly-
siswas originally planned, but the lower rate of renal replace-
ment therapy in the vasopressin-treated patients means that
this could be an important future assessment. Although there
was no difference in the distribution or number of kidney
failure–free days between vasopressin and norepinephrine
groups, the 95% confidence intervals of the difference be-
tweengroupshas anupper limit of 5days in favor of vasopres-
sin,whichwould be clinically important. Therefore, these re-
sults are still consistentwith apotentially clinically important
benefit for vasopressin but a larger trial would be needed to
confirm or refute this.
Conclusions
Among adults with septic shock, the early use of vasopressin
compared with norepinephrine did not improve the number
ofkidneyfailure–freedays.Althoughthese findingsdonotsup-
port the use of vasopressin to replace norepinephrine as ini-
tial treatment in this situation, the confidence interval in-
cludedapotential clinically importantbenefit for vasopressin,
and larger trials may be warranted to assess this further.
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